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the CE of OAB treatments isn’t this simple, however, and
further research is needed to assess changes in resource
consumption due to treatment.
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OBJECTIVES: To compare the estimated ﬁrst-line treat-
ment costs of extended-release tolterodine versus con-
trolled-release oxybutynin in patients with overactive
bladder patients (OAB). METHODS: Data from a 
randomized clinical trial (Curr Med Res Opin 2002;
18:177–184), showing greater improvement in bladder
condition for patients taking extended-release tolterodine
compared to controlled-release oxybutynin (70% vs.
60% in all patients, 75% vs. 54% in patients with prior
therapy, and 69% vs. 61% in treatment naïve patients),
was used to conduct the analyses. The analysis input trial
outcomes into an existing decision analysis model that
had shown extended-release tolterodine was 6.3% less
expensive than controlled-release oxybutynin in terms of
the cost of treatment. Analyses were constructed from the
payer perspective; all costs are given in 2000 U.S. dollars.
RESULTS: The decision analysis model yielded results
that ranged between a 5.7% and 7.0% total cost of 
treatment advantage for extended-release tolterodine in
the treatment of all patients. This cost advantage 
was 5.1%–6.3% for treatment-naïve patients and
8.9%–10.8% for previously treated patients. The varia-
tion in the results depended on the model timeframe
chosen (12, 14, or 16 weeks). Sensitivity analyses showed
these results to be stable. CONCLUSIONS: Results from
these analyses conﬁrm earlier studies that, for patients
with OAB and initiating long-acting pharmacologic
therapy in the primary care setting, treatment with
extended-release tolterodine is less costly than treatment
with controlled-release oxybutynin. Additional studies
directly comparing these treatment alternatives are
needed to further conﬁrm these results.
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OBJECTIVES: Since satisfaction for telemedicine is ill-
deﬁned (Mair, 2000) and no standard measurement tool
is available, we developed a self-administered Question-
naire of the Satisfaction for Telemedicine (QueST).
METHODS: Domains of satisfaction were: 1) global 
satisfaction; 2) user-friendliness; 3) relationship with the
medical center; 4) coping; 5) everyday life; 6) expectations
about telemedicine; and 7) detailed judgment. Answers
were provided through a 4–5 degrees Likert scale; the
overall score was standardized to a maximum value of
100. After a probe technique, the ﬁnal QueST was admin-
istered to 26 patients on telemonitoring (transmission 
of subjective/objective data to an automatic call center 
or web server) for peritoneal dialysis or heart failure.
RESULTS: Mean age of the patients was 57.3 years
(range 43–74); 81% were males. Electronic devices 
(cellular phone or teletext) were daily used by 73% of the
patients, but computer by only 34% of them. Mean sat-
isfaction score was 72 (48–91): 29% of the patients were
highly satisﬁed with telemedicine either by considering
those with an overall score >= 80 or by assessing the
answer in the ﬁrst domain. However, a detailed elicita-
tion of patients judgement on telemedicine showed that
60% of them were very satisﬁed with it. Some users
(24%) declared to have some practical difﬁculties with
telemedicine but 88% of them expected a future beneﬁt
from telemedicine. Both the relations with the referral
center, quality of daily life and coping ability improved
during the period on telemedicine in 73%, 77%, 81% of
the patients, respectively. Willingness to pay for one year
of telemedicine was on average €81: 22% of the patients
were willing to pay for more than €90. CONCLUSIONS:
Acceptability of telemedicine is high and its impact over
the perceived quality of care is relevant. Nevertheless,
patients are willing to have this service included into their
usual health care with no or little extra costs. From the
patients perspective, telemedicine should be implemented
by the National Health Care System.
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OBJECTIVE: To evaluate the role of treatment approach
(CHD or CAPD) on the self-perception of QoL in uremic
patients. Cross-sectional matched pair study of CHD 
and CAPD subjects. METHODS: Sixty-two matched
pairs of patients (30M and 32F), median age 59 years
were studied. The CHD and CAPD groups were similar
for demographic and social variables. Higher percentage
of patients with diuresis >500ml/die and hypertension
were registred in CAPD patients. Nutritional Status was
